MBMartijn H. Den Brok

Martijn H. Den Brok

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martijn H. Den Brok has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Click-to-Release for Controlled Immune Cell Activation: Tumor-Targeted Unmasking of an IL12 Prodrug

    by Martijn H. Den Brok, Kim E. de Roode, Luc H. M. Zijlmans, Laurens H. J. Kleijn, Marleen H. M. E. van Stevendaal, Ron M. Versteegen, Lieke W. M. Wouters, Raffaella Rossin, Marc S. Robillard

    Objectives: Immunotherapy utilizing immune-stimulating cytokines such as IL12 holds great promise for the treatment of cancer. However, clinical use of IL12 is hampered due to severe toxicity following systemic administration. We here present a novel treatment strategy in which IL12 is chemically silenced by conjugation to PEG masks that sterically hinder the receptor binding. Subsequently, the masks can be released on demand using a bioorthogonal click reaction, cleaving the linker connecting the masks, thereby restoring the native cytokine. This “click-to-release” approach is based on the highly selective Inverse electron-demand Diels–Alder (IEDDA) pyridazine elimination reaction between a tetrazine (Tz) and a trans-cyclooctene (TCO), optimized for fast reaction kinetics and in vivo compatibility. Selective activation in the tumor microenvironment is achieved by pretargeting one component of this reaction to the tumor, triggering local activation of the masked IL12 once it is given in a secondary i.v. injection. Methods: IL12 masking and unmasking were evaluated in vitro with PAGE and HEK-Blue reporter cells and ex vivo with ELISA. Biodistribution in mice was evaluated with I-125 radiolabeling and biotin-click histochemistry. Results: Several designs were evaluated and optimized in vitro, resulting in an IL12-TCO-PEG construct that exhibited superior masking and subsequent reactivation upon reaction with a tetrazine bound to a TAG-72-targeted diabody. In tumor-bearing mice, we demonstrated that this diabody-tetrazine could efficiently pre-localize tetrazine in the tumor. Administration of IL12-TCO-PEG 24 h later afforded efficient and selective unmasking in tumors, but not in the blood. Conclusions: These results demonstrate proof of principle of the click-cleavable IL12 prodrug approach and showcase the versatility of the click-to-release reaction.


  • Open Access

    Click-to-release for controlled immune cell activation: tumor-targeted unmasking of an IL12 prodrug

    by Martijn Den Brok, Kim de Roode, Luc Zijlmans, Laurens Kleijn, Marleen van Stevendaal, Ron Versteegen, Lieke Wouters, Raffaella Rossin, Marc Robillard

    Objectives. Immunotherapy utilizing immune stimulating cytokines such as IL12 holds great promise for the treatment of cancer. However, clinical use of IL12 is hampered due to severe toxicity following systemic administration. We here present a novel treatment strategy in which IL12 is chemically silenced by conjugation to PEG masks that can be released on demand using a bioorthogonal click reaction, restoring the native cytokine. This “click-to-release” approach is based on the IEDDA pyridazine elimination reaction between a tetrazine and a trans-cyclooctene (TCO). Selective activation in the tumor microenvironment is achieved by pretargeting one component of this reaction to the tumor, triggering local activation of the masked IL12 once it is given in a secondary i.v. injection. Methods. IL12 masking and unmasking was evaluated in vitro with PAGE and HEK-Blue reporter cells and ex vivo with ELISA. Biodistribution in mice was evaluated with I-125 radiolabeling and biotin-click histochemistry. Results. Several designs were evaluated and optimized in vitro resulting in an IL12-TCO-PEG construct that exhibited superior masking- and subsequent re-activation upon reaction with a tetrazine bound to a TAG-72-targeted diabody. In tumor-bearing mice, we demonstrated that this diabody-tetrazine could efficiently pre-localize tetrazine in the tumor. Administration of IL12-TCO-PEG 24 hrs later afforded efficient and selective unmasking in tumors, but not in blood. Conclusions. These results demonstrate proof of principle of the click-cleavable IL12 prodrug approach and showcase the versatility of the click-to-release reaction.

  • Open Access

    Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial

    by S. van Wilpe, I.S.H. Kloots, P.H.J. Slootbeek, M. Den Brok, H. Westdorp, M D Franken, M. Coskunturk, T. Osinga, H. Bloemendal, G. Adema, et al.


  • Open Access

    Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation

    by Lisa G. M. Huis In ’T Veld, Nataschja I. Ho, Melisssa Wassink, Martijn H. Den Brok, Gosse J. Adema

    Saponin-based adjuvants (SBAs) are promising new adjuvants that stand out as they not only enforce CD4 + T cell-mediated immunity and antibody responses, but also induce an unprecedented level of antigen cross-presentation by dendritic cells (DC) and subsequent CD8 + T cell activation. We discovered that SBA’s ability to boost cross-presentation depends on the induction of lipid bodies (LBs). Moreover, the MHCIIloCD11bhiDC subset was identified to be most responsive to SBA-induced cross-presentation. The aim is to further unravel the mechanisms behind the induction of DC cross-presentation by SBAs. Here we show that SBAs specifically induce the PKR-like Endoplasmic Reticulum kinase (PERK) pathway and that SBA-induced DC cross-presentation is dependent on activation of the PERK pathway. PERK activation and LB formation are both crucial for SBA-induced cross-presentation and PERK inhibition has little or no effect on SBA-induced LB formation. SBA’s responsiveness, LB formation and PERK activation are specific for the MHCIIloCD11bhiDCs. These findings contribute to understanding the pathways involved in SBA-induced cross-presentation and immune activation which will ultimately lead to the development of vaccines with improved efficiency and safety.


  • Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper

    by Joseph P. Erinjeri, Gabriel C. Fine, Gosse J. Adema, Muneeb Ahmed, Julius Chapiro, Martijn Den Brok, Rafael Duran, Stephen J. Hunt, D. Thor Johnson, Jens Ricke, et al.

    We provide a concise report on the current state of the synergies that exist between interventional oncology and immuno-oncology, as well as the future directions of these fields. Interventional oncology is a subspecialty field of interventional radiology that addresses the diagnosis and treatment of cancer and cancer-related problems by using targeted minimally invasive pro...


  • Open Access

    Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation

    by Martijn H. Den Brok, Christian Büll, Melissa Wassink, Annemarie M. de Graaf, Jori A. Wagenaars, Marthe Minderman, Mayank Thakur, Sebastian Amigorena, Eric O. Rijke, Carla C. Schrier, et al.

    Saponin-based adjuvants (SBAs) are being used in animal and human (cancer) vaccines, as they induce protective cellular immunity. Their adjuvant potency is a factor of inflammasome activation and enhanced antigen cross-presentation by dendritic cells (DCs), but how antigen cross-presentation is induced is not clear. Here we show that SBAs uniquely induce intracellular lipid bodies (LBs) in the CD11b+ DC subset in vitro and in vivo. Using genetic and pharmacological interference in models for vaccination and in situ tumour ablation, we demonstrate that LB induction is causally related to the saponin-dependent increase in cross-presentation and T-cell activation. These findings link adjuvant activity to LB formation, aid the application of SBAs as a cancer vaccine component, and will stimulate development of new adjuvants enhancing T-cell-mediated immunity.


  • 996 TLR6 Stimulation Leads to the Increase of TH17-Associated Transcription Factor RoryT in CD4+ T Cells Both In Vitro and In Vivo

    by Mary E. Morgan, Bin Zheng, Martijn H. Den Brok, Henk van de Kant, Pim J. Koelink, Gert Folkerts, Gosse J. Adema, Aletta D. Kraneveld